Veritable, L.P. Biomarin Pharmaceutical Inc Transaction History

Veritable, L.P.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 13, 2020	SELL	$71.87 - $131.03 $148,986 - $271,625	-2,073 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$79.55 - $124.22 $164,907 - $257,508	2,073 New	2,073 $256,000
Q1 2020 May 13, 2020	SELL	$71.37 - $96.85 $181,279 - $245,999	-2,540 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$64.27 - $86.37 $163,245 - $219,379	2,540 New	2,540 $215,000
Q2 2019 Aug 12, 2019	SELL	$80.35 - $93.9 $200,312 - $234,092	-2,493 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$84.2 - $98.62 $209,910 - $245,859	2,493 New	2,493 $221,000
Q4 2018 Feb 14, 2019	SELL	$80.14 - $106.07 $176,708 - $233,884	-2,205 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$93.92 - $105.72 $2,723 - $3,065	29 Added 1.33%	2,205 $214,000
Q2 2018 Aug 13, 2018	BUY	$76.01 - $99.03 $165,397 - $215,489	2,176 New	2,176 $205,000
Q1 2018 May 14, 2018	SELL	$77.67 - $92.63 $276,116 - $329,299	-3,555 Closed	0 $0
Q4 2017 Feb 13, 2018	BUY	$80.76 - $95.13 $287,101 - $338,187	3,555	3,555 $317,000

632

185M

1.63M

1.2M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $13.1B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Veritable, L.P., based on Form 13F filings with the SEC.

Stay updated on Veritable, L.P. with notifications on news.